236
Participants
Start Date
June 30, 2015
Primary Completion Date
January 31, 2016
Study Completion Date
January 31, 2016
AGN-223575 ophthalmic solution
AGN-223575 ophthalmic solution once or twice daily
AGN-223575 vehicle ophthalmic solution
Vehicle to AGN22375 ophthalmic solution once or twice daily.
Raymond Fong MD, PC, New York
South Shore Eye Care LLP, Wantagh
Cornerstone Eye Care, High Point
SE Clinical Research Associates, LLC/ Charolette Eye Ear Nose, Charlotte
Bluestein Custom Vision, Charleston
Carolinas Centers for Sight, PC, Florence
Coastal Research Assoc. LLC, Roswell
Eye Care Centers Management, Inc., Morrow
West Coast Eye Institute, Lecanto
Kentucky Center for Vision, Lexington
Eye Care Associates of Greater Cincinnati, Cincinnati
Black Hills Regional Eye Institute, Rapid City
Chicago Cornea Consultants, Hoffman Estates
Comprehensive Eye Care Ltd., Washington
Ophthalmology Associates, St Louis
Moyes Eye Center, Kansas City
Durrie Vision, Overland Park
Houston Eye Associates, Houston
Whitsett Vision Group, Houston
Medical Center Opth. Assoc., San Antonio
Keystone Clinical Research, Austin
Eye Associates of Colorado Springs, Colorado Springs
Arizona Center for Clinical Trials, Phoenix
Specialty Eye Ctr. Med. Group, Glendale
The Eye Research Foundation, Newport Beach
WCCT Global, Santa Ana
Mark A. Terry, MD PC/ Devers Eye Institute, Portland
Tufts Medical Center/ Tufts University School of Medicine, Boston
Lead Sponsor
Allergan
INDUSTRY